Biosimilars Market Research Reports & Industry Analysis
The worldwide prescription generic drug market has stood the test of time and has endured numerous growing pains. However, it has evolved into a formidable and important participant in the complex world of health care. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market.
Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for the promotion of biosimilars is favorable in the next five years.
Biosimilars Industry Research & Market Reports
-
Global Biosimilars Market Size study, By Product (Monoclonal Antibodies, Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Interferons, Enoxaparin Sodium, Glucagon, Calcitonin), By Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Indications), and Regional Forecasts 2022-2028
... Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Indications), and Regional Forecasts 2022-2028 Global Biosimilars Market is valued at approximately USD 15.60 Billion in 2021 and is anticipated to grow with a healthy growth rate ... Read More
-
Global Human Insulin Market Size study, By Product Type (Insulin Analogs and Biosimilars (Rapid-acting, Long-acting, Premixed), Human Insulin Biologics (Short-acting, Intermediate-acting, Premixed)), By Type (Insulin Analogs and Biosimilars (Long-Acting Biosimilars, Rapid-Acting Biosimilars, Premixed Biosimilars), HI Biologics (Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics)), By Delivery Devices (Pens, Pen Needles, Syringes), By Brand (Insulin Analogs and Biosimilars (Lantus, NovoRapid/Novolog, Humalog, Other Brands), Human Insulin Biologics (Actrapid, Insulatard, and Mixtard, Humulin, Insuman)), By Application (Type I Diabetes, Type II Diabetes), and Regional Forecasts 2022-2028
... Biologics (Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics)), By Delivery Devices (Pens, Pen Needles, Syringes), By Brand (Insulin Analogs and Biosimilars (Lantus, NovoRapid/Novolog, Humalog, Other Brands), Human Insulin Biologics (Actrapid, Insulatard, and Mixtard, Humulin, Insuman)), By ... Read More
-
North America Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)
... (Mammalian and Microbial-Based Biologics/Non-Mammalian) The biopharmaceutical contract manufacturing market in North America is expected to grow from US$ 7,127.97 million in 2021 to US$ 12,847.38 million by 2028; it is estimated to register a CAGR ... Read More
-
Europe Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)
... and Microbial-Based Biologics/Non-Mammalian) The biopharmaceutical contract manufacturing market in Europe is expected to grow from US$ 4,610.37 million in 2021 to US$ 8,026.13 million by 2028; it is estimated to register a CAGR of 8.2% ... Read More
-
Metastatic Cancer Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous, Intramuscular, Oral, and Others), Drug Class (HER2 Inhibitor, Immune Checkpoint Inhibitor, PARP Inhibitor, Kinase Inhibitor, and Others), Product (Branded and Generic & Biosimilar), and End User (Hospital, Specialty Clinic, and Others)
... (Intravenous, Intramuscular, Oral, and Others), Drug Class (HER2 Inhibitor, Immune Checkpoint Inhibitor, PARP Inhibitor, Kinase Inhibitor, and Others), Product (Branded and Generic & Biosimilar), and End User (Hospital, Specialty Clinic, and Others) The metastatic cancer ... Read More
-
Asia Pacific Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)
... (Mammalian and Microbial-Based Biologics/Non-Mammalian) The biopharmaceutical contract manufacturing market in Asia-Pacific is expected to grow from US$ 2,973.92 million in 2021 to US$ 5,462.23 million by 2028; it is estimated to register a CAGR of ... Read More
-
Middle East and Africa Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)
... and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian) The biopharmaceutical contract manufacturing market in Middle East & Africa is expected to grow from US$ 457.89 million in 2021 to US$ 666.06 million by 2028; it is estimated ... Read More
-
South and Central America Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Biologics and Biosimilar), Service (Process Development, Fill and Finish Operation, Analytical and QC Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian)
... and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian) The biopharmaceutical contract manufacturing market in South and Central America is expected to grow from US$ 564.89 million in 2021 to US$ 866.71 million by 2028; it is estimated ... Read More
-
2022 Global Biosimilars Industry (2028 Outlook)
... market size data for a three-year historical trend (2016-2019), a three-year forecast estimate trends (2020-2023), and a five-year outlook projection (2023-2028) for 46 countries. Market and product shipments include the total value of all products ... Read More
-
Impact of Mexico on the Pharmaceutical Industry - Thematic Research
... high drug prices. Low-cost manufacturing of pharmaceuticals is attracting increasing foreign investment to Mexico. Many US manufacturing companies aiming to reduce dependence on China perceive nearshoring to Mexico or Canada as even more advantageous than ... Read More
-
Global Protein Engineering Market Size study, By Product & Services (Instruments, Consumables, Software & Services), By Protein Type (Monoclonal Antibodies, Erythropoietin, Interferons, Vaccines, Colony-stimulating Factors, Growth Hormones, Coagulation Factors, Other Proteins), By Technology (Rational Protein Design, Irrational Protein Design), By End User (Biopharmaceutical Companies, Contract Research Organizations, Academic Research Institutes), and Regional Forecasts 2022-2028
... Design, Irrational Protein Design), By End User (Biopharmaceutical Companies, Contract Research Organizations, Academic Research Institutes), and Regional Forecasts 2022-2028 Global Protein Engineering Market is valued approximately USD 2.47 billion in 2021 and is anticipated to ... Read More
-
Global Downstream Processing Market Size study, By Product (Chromatography Columns and Resins, Filters, Membrane Adsorbers, Single-use Products, Other Products), By Technique (Purification, Solid-liquid Separation, Clarification/Concentration), By Application (Monoclonal Antibody Production, Vaccine Production, Insulin Production, Immunoglobulin Production, Erythropoietin Production, Other Applications), By End User (Biopharmaceutical Manufacturers, Contract Manufacturing Organizations (CMOs)), and Regional Forecasts 2022-2028
... Production, Erythropoietin Production, Other Applications), By End User (Biopharmaceutical Manufacturers, Contract Manufacturing Organizations (CMOs)), and Regional Forecasts 2022-2028 Global Downstream Processing Market is valued approximately USD 22.05 billion in 2021 and is anticipated to grow ... Read More
-
Middle East and Africa Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
... & antibody-like proteins, and Biosimilar antibody products) The Middle East and Africa (MEA) next-generation antibody market is expected to reach US$ 450.75 million by 2028 from US$ 222.59 million in 2021. It is estimated to ... Read More
-
North America Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
... proteins, and Biosimilar antibody products) The North America next-generation antibody market is expected to reach US$ 5,428.80 million by 2028 from US$ 2,457.09 million in 2021. It is estimated to grow at a CAGR of ... Read More
-
Europe Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
... and Biosimilar antibody products) The Europe next-generation antibody market is expected to reach US$ 3,162.30 million by 2028 from US$ 1,455.32 million in 2021. It is estimated to grow at a CAGR of 11.7% from ... Read More
-
South and Central America Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
... & antibody-like proteins, and Biosimilar antibody products) The South and Central America (SCAM) next-generation antibody market are expected to reach US$ 695.60 million by 2028 from US$ 333.92 million in 2021. It is estimated to ... Read More
-
Asia Pacific Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
... proteins, and Biosimilar antibody products) The Asia Pacific (APAC) next-generation antibody market is expected to reach US$ 2,312.68 million by 2028 from US$ 999.49 million in 2021. It is estimated to grow at a CAGR ... Read More
-
Biopharmaceutical Contract Manufacturing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Biologics and Biosimilar); Service (Process Development, Fill and Finish Operations, Analytical and Quality Control Studies, and Packaging), and Source (Mammalian and Microbial-Based Biologics/Non-Mammalian), and Geography
... and Microbial-Based Biologics/Non-Mammalian), and Geography The biopharmaceutical contract manufacturing market is projected to reach US$ 27,868.50 million by 2028 from US$ 15,735.04 million in 2021; it is expected to grow at a CAGR of 8.5% ... Read More
-
Global Generic Drugs Market; By Product Type (Simple Generics, Super Generics, and Biosimilars); By Route of Administration (Oral, Topical, Injectable, and Others); By Application (Cardiovascular Products, Anti-infective Drugs, Central Nervous System Drugs, Anti-cancer Drugs, Respiratory Products, and Others); By Distribution Channel (Hospitals/Clinics, Retail Pharmacies, and Online Pharmacies); By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2018-2028
... Products, and Others); By Distribution Channel (Hospitals/Clinics, Retail Pharmacies, and Online Pharmacies); By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2018-2028 Generic Drugs Market ... Read More
-
India Generic Drugs Market; By Product Type (Simple Generics, Super Generics, and Biosimilars); By Route of Administration (Oral, Topical, Injectable, and Others); By Application (Cardiovascular Products, Anti-infective Drugs, Central Nervous System Drugs, Anti-cancer Drugs, Respiratory Products, and Others); By Distribution Channel (Hospitals/Clinics, Retail Pharmacies, and Online Pharmacies); Trend Analysis, Competitive Market Share & Forecast, 2018-2028
... Products, and Others); By Distribution Channel (Hospitals/Clinics, Retail Pharmacies, and Online Pharmacies); Trend Analysis, Competitive Market Share & Forecast, 2018-2028 India Generic Drugs Market to Grow at 11% during 2022 – 2028 India generic drugs ... Read More
-
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change Including: 1) By Application: Chemotherapy Induced Neutropenia; Transplantation; Others 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Mail-Order Pharmacies Covering: Coherus BioSciences; Biocon/Mylan; Sandoz (Novartis); Intas Biopharmaceuticals Ltd.; Mundipharma GmbH
... pegfilgrastim biosimilars market as it emerges from the COVID 19 shut down. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies. Understand how the ... Read More
-
Ranibizumab biosimilars - Insight, 2022
... and nonclinical stage products. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It ... Read More
-
Global Healthcare Digital Experience Platform Market By Component (Platform (without services), and Services), By Application (Business-to-Consumer (B2C), Business-to-Business (B2B), and Others), By Delivery Mode (Cloud and On-premise), By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027
... 2021 - 2027 The Global Healthcare Digital Experience Platform Market size is expected to reach $2.1 billion by 2027, rising at a market growth of 12.8% CAGR during the forecast period. The term Digital Experience ... Read More
-
Europe Healthcare Digital Experience Platform Market By Component (Platform (without services), and Services), By Application (Business-to-Consumer (B2C), Business-to-Business (B2B), and Others), By Delivery Mode (Cloud and On-premise), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
... - 2027 The Europe Healthcare Digital Experience Platform Market would witness market growth of 12.0% CAGR during the forecast period (2021-2027). For instance, cloud enablement can make life lot simpler for a hospital. A hospital ... Read More
-
Global Biologics CDMO Market (2022 Edition) - Analysis By Type (Mammalian, Non-Mammalian), Product Type (Biologics, Biosimilars), By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2021-2026)
... research report, the global Biologics CDMO Market was valued at USD 9.9 Billion in the year 2020. Growth opportunities for the Biologics CDMO market is attributed to the growth of the geriatric population, rising technical ... Read More
Research Assistance
